We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
Read MoreHide Full Article
Exact Sciences Corporation (EXAS - Free Report) will present 10 abstracts demonstrating the breadth and depth of the company’s screening and diagnostic portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 31 to Jun 4, 2024. The data that will be provided expands the body of evidence surrounding the predictive and prognostic utility of the Oncotype DX test in all racial and ethnically diverse patients.
Exact Sciences will also present data on their approach to multi-cancer early detection (MCED) across several tumor types and new real-world evidence demonstrating optimized screening adherence techniques for the Cologuard test and high adherence rates for repeat screening.
Highlights of Data Presented
According to new data from two studies that evaluated Recurrence Score results, the Oncotype DX Breast Recurrence Score test predicted breast cancer survival across racial and ethnic groups. Following propensity score-adjusted analysis, the test was found to be prognostic for breast cancer-specific mortality and predictive of chemotherapy benefits across racial and ethnic groups in lymph node-negative patients.
A study of more than 171,000 breast cancer patients shows that non-Hispanic Black patients had higher Recurrence Score results and chemotherapy usage compared with other groups. The RxPONDER trial demonstrated that non-Hispanic Black patients had higher proliferation axis scores, suggesting differences in tumor biology may explain differences in breast cancer outcomes.
A new study reveals that multi-cancer early detection (MCED) can help patients discover tumors sooner, resulting in shorter diagnosis times and fewer late-stage (Stage IV) diagnoses.
Exact Sciences will also present real-world results highlighting strong adherence and a three-year repeat rate for the Cologuard test. It will offer data illustrating the effectiveness of adopting various digital outreach tactics to promote screening adherence, resulting in high screening completion rates for the Cologuard test across various patient categories.
Significance of Recent Study Outcomes
Exact Sciences' expanding research demonstrates that earlier and more customized therapeutic interventions result in greater success for cancer patients. As a result, effective cancer screening and diagnostic techniques are essential for improving patient outcomes.
These statistics presented at ASCO will help Exact Sciences achieve its aim of setting new screening and diagnostic standards for cancer care through rigorous innovation and real-world data collection.
Image Source: Zacks Investment Research
New data demonstrates EXAS’ dedication toward innovation and tactics that improve access to effective cancer screening and diagnostic tools for patients.
Industry Prospects
Per Grand View Research, the global cancer diagnostics market size was estimated at $107.45 billion in 2023 and is expected to witness a CAGR of 6.16% from 2024 to 2030. The upside can be attributed to the growing prevalence of cancer, technological advancements in diagnostics procedures and rising initiatives undertaken by private and public organizations.
Other Notable Highlights
In April 2024, Exact Sciences reported a promising outcome for the non-endoscopic Oncoguard Esophagus test, developed in collaboration with the Mayo Clinic Comprehensive Cancer Center. The test, currently in development for the detection of esophageal adenocarcinoma (EAC) and its precursors, including Barrett’s esophagus (BE), has demonstrated high sensitivity and specificity.
In March 2024, Exact Sciences announced the online publication of the BLUE-C study results in The New England Journal of Medicine (NEJM). The 20,000-participant, multi-center and prospective study was designed to determine the performance characteristics of the company’s next-generation Cologuard Plus multitarget stool DNA test. The BLUE-C study results demonstrated that Cologuard Plus met all the endpoints, achieving 94% CRC sensitivity, 91% specificity including non-advanced findings and 93% specificity including no findings.
Price Performance
In the past six months, the stock has declined 23.4% compared with the industry’s rise of 6.2%.
Zacks Rank and Key Picks
Exact Sciences currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Medpace (MEDP - Free Report) , ResMed (RMD - Free Report) and Encompass Health Corporation (EHC - Free Report) .
Medpace, sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2024 earnings per share (EPS) of $3.20. The figure beat the Zacks Consensus Estimate by 30.6%. Revenues of $511 million increased 17.7% from last year’s comparable figure. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace has an estimated 2024 earnings growth rate of 26.5% compared with the industry’s 12.3%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 12.8%.
ResMed, sporting a Zacks Rank #2, reported first-quarter 2024 EPS of $2.13, which topped the Zacks Consensus Estimate by 10.9%. Revenues of $1.20 billion surpassed the Zacks Consensus Estimate by 1.9%.
RMD has an estimated fiscal 2024 earnings growth rate of 17.9% compared with the industry’s 15.7%. In each of the trailing four quarters, the company delivered an average earnings surprise of 2.8%.
Encompass Health, carrying a Zacks Rank #2, reported first-quarter 2024 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 20.4%. Net operating revenues of $1.3 billion topped the Zacks Consensus Estimate by 3.6%.
EHC has an estimated long-term earnings growth rate of 15.6% compared with the industry’s 11.7% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.7%.
Image: Bigstock
Exact Sciences (EXAS) to Showcase Favorable Research Outcome
Exact Sciences Corporation (EXAS - Free Report) will present 10 abstracts demonstrating the breadth and depth of the company’s screening and diagnostic portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 31 to Jun 4, 2024. The data that will be provided expands the body of evidence surrounding the predictive and prognostic utility of the Oncotype DX test in all racial and ethnically diverse patients.
Exact Sciences will also present data on their approach to multi-cancer early detection (MCED) across several tumor types and new real-world evidence demonstrating optimized screening adherence techniques for the Cologuard test and high adherence rates for repeat screening.
Highlights of Data Presented
According to new data from two studies that evaluated Recurrence Score results, the Oncotype DX Breast Recurrence Score test predicted breast cancer survival across racial and ethnic groups. Following propensity score-adjusted analysis, the test was found to be prognostic for breast cancer-specific mortality and predictive of chemotherapy benefits across racial and ethnic groups in lymph node-negative patients.
A study of more than 171,000 breast cancer patients shows that non-Hispanic Black patients had higher Recurrence Score results and chemotherapy usage compared with other groups. The RxPONDER trial demonstrated that non-Hispanic Black patients had higher proliferation axis scores, suggesting differences in tumor biology may explain differences in breast cancer outcomes.
A new study reveals that multi-cancer early detection (MCED) can help patients discover tumors sooner, resulting in shorter diagnosis times and fewer late-stage (Stage IV) diagnoses.
Exact Sciences will also present real-world results highlighting strong adherence and a three-year repeat rate for the Cologuard test. It will offer data illustrating the effectiveness of adopting various digital outreach tactics to promote screening adherence, resulting in high screening completion rates for the Cologuard test across various patient categories.
Significance of Recent Study Outcomes
Exact Sciences' expanding research demonstrates that earlier and more customized therapeutic interventions result in greater success for cancer patients. As a result, effective cancer screening and diagnostic techniques are essential for improving patient outcomes.
These statistics presented at ASCO will help Exact Sciences achieve its aim of setting new screening and diagnostic standards for cancer care through rigorous innovation and real-world data collection.
New data demonstrates EXAS’ dedication toward innovation and tactics that improve access to effective cancer screening and diagnostic tools for patients.
Industry Prospects
Per Grand View Research, the global cancer diagnostics market size was estimated at $107.45 billion in 2023 and is expected to witness a CAGR of 6.16% from 2024 to 2030. The upside can be attributed to the growing prevalence of cancer, technological advancements in diagnostics procedures and rising initiatives undertaken by private and public organizations.
Other Notable Highlights
In April 2024, Exact Sciences reported a promising outcome for the non-endoscopic Oncoguard Esophagus test, developed in collaboration with the Mayo Clinic Comprehensive Cancer Center. The test, currently in development for the detection of esophageal adenocarcinoma (EAC) and its precursors, including Barrett’s esophagus (BE), has demonstrated high sensitivity and specificity.
In March 2024, Exact Sciences announced the online publication of the BLUE-C study results in The New England Journal of Medicine (NEJM). The 20,000-participant, multi-center and prospective study was designed to determine the performance characteristics of the company’s next-generation Cologuard Plus multitarget stool DNA test. The BLUE-C study results demonstrated that Cologuard Plus met all the endpoints, achieving 94% CRC sensitivity, 91% specificity including non-advanced findings and 93% specificity including no findings.
Price Performance
In the past six months, the stock has declined 23.4% compared with the industry’s rise of 6.2%.
Zacks Rank and Key Picks
Exact Sciences currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Medpace (MEDP - Free Report) , ResMed (RMD - Free Report) and Encompass Health Corporation (EHC - Free Report) .
Medpace, sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2024 earnings per share (EPS) of $3.20. The figure beat the Zacks Consensus Estimate by 30.6%. Revenues of $511 million increased 17.7% from last year’s comparable figure. You can see the complete list of today’s Zacks #1 Rank stocks here.
Medpace has an estimated 2024 earnings growth rate of 26.5% compared with the industry’s 12.3%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average being 12.8%.
ResMed, sporting a Zacks Rank #2, reported first-quarter 2024 EPS of $2.13, which topped the Zacks Consensus Estimate by 10.9%. Revenues of $1.20 billion surpassed the Zacks Consensus Estimate by 1.9%.
RMD has an estimated fiscal 2024 earnings growth rate of 17.9% compared with the industry’s 15.7%. In each of the trailing four quarters, the company delivered an average earnings surprise of 2.8%.
Encompass Health, carrying a Zacks Rank #2, reported first-quarter 2024 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 20.4%. Net operating revenues of $1.3 billion topped the Zacks Consensus Estimate by 3.6%.
EHC has an estimated long-term earnings growth rate of 15.6% compared with the industry’s 11.7% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.7%.